
Eliminates subjectivity and variability of histologic grade
PreciseBreast® was validated in a landmark trial utilizing H&E slides in 1,607 patients from the NSABP B‑20 study providing level 1B evidence for women with hormone receptor positive, node negative, early-stage invasive breast cancer. Median follow-up from randomized ET+CT vs. ET alone arms was 14.2 years. Study objectives validated were the prognostic performance of PreciseBreast® for distant recurrence, the reporting of adjuvant chemotherapy benefit, and the comparison of AI-Grade to histologic grade.
For newly diagnosed women with invasive ductal carcinoma HR+, HER2-, Node -, any menopausal status, no prior treatment.3 10
View Full Poster


OncoIntelligence™ analyzes a digitized H&E-stained slide and quantifies the morphologic features & clinical factors that impact the risk of disease recurrence.

PreciseDx first digitizes the same diagnostic H&E-stained slide a pathologist would use for tumor grading.

OncoIntelligence, our AI-platform, analyzes every cell from the digitized image, objectively quantifying morphologic features that reliably predict 10-year risk of distant recurrence.
Pathologists perform Inference Quality Control to optimize the areas of tumor focus.

The proprietary algorithm delivers the quantitative assessment of the morphologic features as an AI-Grade alone or an AI-Grade that includes 4 clinical factors that measure a patient's 10-year individual risk of distant recurrence.

PreciseBreast AI-Grade is the output of the proprietary algorithm.
PreciseBreast® delivers meaningful cost savings and better patient outcomes to healthcare systems.
PreciseBreast® requires no additional procedures or specialized staff for specimen collection, and it can be accessed from any geographical area in the US or the world.
PreciseBreast® delivers benefits for physicians, patients and payors.
10-year distant recurrence risk
Earlier results lessen anxiety for patients
Lower overall testing and treatment costs
Worldwide access to PreciseBreast®
Oct 27, 2026
ESMO 26: AI Digital Pathology Models Estimate Chemotherapy Benefit and Risk of Distant Recurrence in Patients From the NSABP B-20 Study
See More
Oct 27, 2026
ESMO 26: AI Digital Pathology Models Estimate Chemotherapy Benefit and Risk of Distant Recurrence in Patients From the NSABP B-20 Study
See More
Dec 4, 2025
PreciseDx Presents New Data for PreciseBreast, an AI Digital Pathology Test to Predict Breast Cancer Recurrence, at the 2025 San Antonio Breast Cancer Symposium
See More
Dec 4, 2025
PreciseDx, the leading innovator behind PreciseBreast, a novel AI digital pathology test, announces the upcoming presentation of three abstracts that further validate the test's ability to assess risk of recurrence in early-stage breast cancer. Ongoing studies aim to demonstrate PreciseBreast's ability to predict treatment benefit.
See More
Aug 20, 2025
External validation of PreciseBreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands
See More
Aug 20, 2025
Current clinical guidelines recommend gene expression profiling to guide treatment in early-stage breast cancer. PreciseBreast (PDxBR) is a digital prognostic tool that integrates artificial intelligence (AI)-derived features from hematoxylin and eosin (H&E) slides with clinicopathologic data to predict recurrence risk. This study externally validated PDxBR in an independent cohort and compared its performance to other risk models.
See More
Contact us today to learn more.
